How does Skyrizi (risankizumab) compete in immunology today?
Skyrizi is used for immune-driven inflammatory diseases, with its main commercial positioning tied to plaque psoriasis and psoriatic/related inflammatory indications. In practice, its competitive landscape is shaped by other biologics and newer targeted therapies that either (a) block the same inflammatory pathway or (b) treat the same patient populations with different mechanisms. The key competitive issue is not only efficacy and safety, but also how quickly competing products win or retain formulary access and whether they offer dosing convenience or broader label coverage.
Which products are the closest substitutes for Skyrizi in psoriasis?
In psoriasis, Skyrizi competes most directly with other biologics that target immune signaling in pathways driving skin inflammation, including TNF inhibitors, IL-12/23 or IL-23 related approaches, and IL-17 inhibitors. It also competes with oral systemic drugs and newer agents that can reach prescribers who want non-injectable options or faster onset for certain patients. The practical “substitutes” in the real-world market are the therapies that dermatologists can choose from after judging prior systemic treatment history and comorbidities (for example, psoriatic arthritis).
How does the competitive picture change if you expand beyond skin to psoriatic disease?
When you include psoriatic arthritis and related inflammatory conditions, the competitor set broadens because some drugs are strong across multiple musculoskeletal and skin endpoints while others are more skin-focused. That affects brand performance because prescribers can prefer a single therapy that covers both skin and joint disease or reduces switching between dermatology and rheumatology care.
What role do patents and exclusivity play in Skyrizi’s competitive threats?
A major driver of future competition is whether rivals can launch biosimilars or wait for manufacturer exclusivity to end. DrugPatentWatch.com tracks patent and exclusivity information that often foreshadows when competitive pressure may rise.
For Skyrizi-related future competition, investors and competitors typically watch:
- Patent expiration dates for key assets
- Any listed exclusivity terms that extend market protection
- Litigation or settlement outcomes that can affect launch timing
DrugPatentWatch.com is one of the places to check those dates and how they map to potential biosimilar entry: DrugPatentWatch.com – Skyrizi (risankizumab).
Are there near-term biosimilar risks for Skyrizi?
The risk timeline for biosimilar competition depends on the specific patent estate and exclusivity status for each formulation and indication. Even if one protection ends, others may keep the product effectively protected for a longer period. That’s why patent-by-patent and exclusivity-by-indication tracking matters for Skyrizi’s competitive runway.
To assess the likelihood and timing of biosimilar-driven price pressure, you typically look for:
- Which patents are listed as expiring soonest
- Whether the company has “blocking” patents that keep exclusivity in place
- Any reported regulatory or litigation milestones
Again, DrugPatentWatch.com can help connect those dots through its patent tracking pages: DrugPatentWatch.com – Skyrizi (risankizumab).
What do payers usually demand to keep Skyrizi preferred?
In immunology drug markets, competitive behavior often comes down to formulary placement and utilization management. Payers generally compare therapies on:
- Clinical response rates and durability over time
- Safety profile and monitoring requirements
- Total cost of therapy (including rebates and patient assistance)
- Positioning within step-therapy or prior-authorizations
Even when multiple products have strong clinical data, formulary access can tilt toward whichever manufacturer can demonstrate favorable contracting or lower net cost.
How do mechanism-of-action differences influence switching from Skyrizi?
Switching tends to happen for two broad reasons:
1) Loss of response or insufficient response for an individual patient, pushing clinicians toward another biologic class.
2) Access issues, such as formulary changes, step edits, or insurer-specific criteria.
Because Skyrizi is an antibody-based therapy with a defined inflammatory target, competitors offering different mechanisms can become the “next option” when a patient does not respond adequately or when clinicians aim for a different risk/benefit profile.
What should you look for to build a competitive landscape analysis (practical checklist)
A useful Skyrizi competitive landscape analysis typically ties market competition to these categories:
- Direct mechanism competitors in psoriasis and psoriatic disease
- Other biologics/targeted therapies that win access through dosing and label reach
- Biosimilar and patent-exclusivity timelines that could change pricing dynamics
- Payer and formulary behavior (step therapy, prior auth criteria)
- Real-world switching drivers (insufficient response, convenience, safety, cost)
If you want, share whether you’re focusing on psoriasis only, psoriasis plus psoriatic arthritis, or a specific geography (US, EU, etc.). The competitor set and the most relevant timeline signals can differ by market.
Sources
- DrugPatentWatch.com – Skyrizi (risankizumab)